Search results
Results from the WOW.Com Content Network
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The Randomised Evaluation of COVID-19 Therapy (RECOVERY Trial) [1] is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection. [2] [3] [4] The trial was later expanded to Indonesia, Nepal and Vietnam. [5]
The Oxford Vaccine Group (OVG) is a vaccine research group within the Department of Paediatrics at the University of Oxford.It was founded in 1994 by Professor E. Richard Moxon, was initially based at the John Radcliffe Hospital, and moved in 2003 to its current location in the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) at the Churchill Hospital in Oxford, England. [1]
The Clinical Trial Service Unit (CTSU) is a medical research institute within the Nuffield Department of Population Health at Oxford University. It primarily conducts large scale clinical trials (phase III – Final Testing) and epidemiological studies of chronic diseases, especially cancer and vascular conditions. [ 1 ]
AstraZeneca's COVID-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in Chile, Peru and the United States, the company said on ...
A study on the effectiveness of a first dose of the Pfizer–BioNTech or Oxford–AstraZeneca COVID-19 vaccines against COVID-19 related hospitalisation in Scotland was based on a national prospective cohort study of 5.4 million people. Between 8 December 2020 and 15 February 2021, 1,137,775 participants were vaccinated in the study, 490,000 of ...
In June 2024, the FDA approved Arexvy for use in people aged 50 to 59 years of age who are at an increased risk of RSV-caused lower respiratory tract disease. [11] The approval is based on data from a phase III study (NCT05590403), [ 44 ] which showed that immune responses were non-inferior in people aged 50–59 years of age at increased risk ...
[2] [14] [15] [16] In the expanded cohort, there were a mean of 6.8 UTIs/year pre-vaccination, the UTI-free rate over the 9-month post-vaccination period was 40.6%, the reduction of infection rate was 75.3% for this period relative to the year prior to vaccination, and 80.3% reported being moderately or markedly improved at 12-month follow-up ...